Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
The historical data trend for Senzime AB's Total Payout Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:6YC vs ABT, SYK, MDT: Total Payout Ratio Comparison
For the Medical Devices subindustry, Senzime AB's Total Payout Ratio, along with its competitors' market caps and Total Payout Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Senzime AB Total Payout Ratio vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Senzime AB's Total Payout Ratio distribution charts can be found below:
* The bar in red indicates where Senzime AB's Total Payout Ratio falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Senzime AB (FRA:6YC) has a Total Payout Ratio of 0.02 as of Aug. 19, 2026. Total Payout Ratio is the percent a company has paid to its shareholders through net repurchase of shares and dividends based on its Net Income. View historical data on Senzime AB and its competitors.
Is Senzime AB's Total Payout Ratio too high?
Senzime AB's current Total Payout Ratio is 0.02. Overall, Senzime AB has a GF Score™ of 59/100, reflecting its overall financial health beyond just this single metric.
How does Senzime AB's Total Payout Ratio compare to ABT and SYK?
Senzime AB's Total Payout Ratio of 0.02 can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Payout Ratio for a Medical Devices & Instruments company?
A good Total Payout Ratio depends on the Medical Devices & Instruments industry context. However, Total Payout Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Payout Ratio mean?
A high Total Payout Ratio can signal that a stock is expensive relative to its fundamentals. Total Payout Ratio is the percent a company has paid to its shareholders through net repurchase of shares and dividends based on its Net Income. View historical data on Senzime AB and its competitors. Senzime AB's current Total Payout Ratio is 0.02. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Senzime AB stock overvalued right now?
Senzime AB (FRA:6YC) has a current Total Payout Ratio of 0.02. The stock's GF Value™ is €0.80, compared to a current price of €0.33 — trading 58.3% below its estimated fair value. The current Total Payout Ratio is 0.02. Senzime AB's overall GF Score™ is 59/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Payout Ratio calculated?
Total Payout Ratio is calculated from a company's financial statements. For Senzime AB (FRA:6YC), the current Total Payout Ratio is 0.02 as of Aug. 19, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Senzime AB (FRA:6YC) Overvalued in 2026?
Based on GuruFocus' analysis, Senzime AB stock appears to be undervalued.
The current stock price of €0.33 is trading 58.3% below its estimated GF Value™ of €0.80.
Key valuation signals for FRA:6YC:
Total Payout Ratio: 0.02
GF Value™: €0.80 vs. price of €0.33 (58.3% below fair value)
No single metric tells the full story. See the FRA:6YC stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Senzime AB is a medical device company developing precision-based patient monitoring solutions for patients undergoing anesthesia. The company develops and markets precision-based monitoring systems for monitoring neuromuscular function and respiration during and after surgery, as well as for intensive care. Its product portfolio includes Next-generation TetraGraph, TetraGraph connectivity, TetraGraph for pediatric, Classic TetraGraph, and ExSpiron. The TetraGraph system is used in thousands of operating rooms internationally in university hospitals, public, private, military, and veterans hospitals. Senzime has direct sales resources in the USA and Germany and collaborates with distributors and licensees in its other main markets.
59GF Score
Get the complete analysis for FRA:6YC
Total Payout Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:6YC has been successfully added to your 
